METase/lncRNA HULC/FoxM1 reduced cisplatin resistance in gastric cancer by suppressing autophagy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
METase/lncRNA HULC/FoxM1 reduced cisplatin resistance in gastric cancer by suppressing autophagy
Authors
Keywords
Methioninase, Cisplatin resistance, lncRNA HULC, FoxM1, Gastric cancer
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume 145, Issue 10, Pages 2507-2517
Publisher
Springer Science and Business Media LLC
Online
2019-09-04
DOI
10.1007/s00432-019-03015-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Downregulation of Long Non-coding RNA FALEC Inhibits Gastric Cancer Cell Migration and Invasion Through Impairing ECM1 Expression by Exerting Its Enhancer-Like Function
- (2019) Huazhang Wu et al. Frontiers in Genetics
- Long non‐coding RNA highly up‐regulated in liver cancer promotes epithelial‐to‐mesenchymal transition process in oral squamous cell carcinoma
- (2019) Wen Su et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Efficacy of Recombinant Methioninase (rMETase) on Recalcitrant Cancer Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models: A Review
- (2019) Kawaguchi et al. Cells
- Long non-coding RNA HULC activates HBV by modulating HBx/STAT3/miR-539/APOBEC3B signaling in HBV-related hepatocellular carcinoma
- (2019) Yunxia Liu et al. CANCER LETTERS
- The mechanism study of lentiviral vector carrying methioninase enhances the sensitivity of drug-resistant gastric cancer cells to Cisplatin
- (2018) Lin Xin et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma
- (2018) Kentaro Igarashi et al. CANCER LETTERS
- Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer
- (2018) Kei Kawaguchi et al. CELL CYCLE
- Long noncoding RNA HULC accelerates liver cancer by inhibiting PTEN via autophagy cooperation to miR15a
- (2018) Xiaoru Xin et al. Molecular Cancer
- METase promotes cell autophagy via promoting SNHG5 and suppressing miR-20a in gastric cancer
- (2018) Lin Xin et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer
- (2017) Hu YiRen et al. Molecular Cancer
- LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells
- (2017) H Xiong et al. ONCOGENE
- The lncRNA HULC functions as an oncogene by targeting ATG7 and ITGB1 in epithelial ovarian carcinoma
- (2017) Shuo Chen et al. Cell Death & Disease
- RNF168 cooperates with RNF8 to mediate FOXM1 ubiquitination and degradation in breast cancer epirubicin treatment
- (2016) M Kongsema et al. Oncogenesis
- Targeting autophagy to overcome drug resistance in cancer therapy
- (2015) Ankit Kumar et al. Future Medicinal Chemistry
- miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2
- (2015) Y An et al. Cell Death & Disease
- Treatment of gastric cancer
- (2014) Michele Orditura WORLD JOURNAL OF GASTROENTEROLOGY
- Methionine depletion with recombinant methioninase:In vitroandin vivoefficacy against neuroblastoma and its synergism with chemotherapeutic drugs
- (2008) Jian Hu et al. INTERNATIONAL JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now